T1	Phenotype	22 39	tumour regression
T2	Phenotype	44 61	improved survival
T3	Disease	76 107	BRAF -mutated melanoma patients
T4	Pharmacodynamic_phenotype	111 162	response to treatment with vemurafenib demonstrates
T5	Gene_or_protein	195 211	BRAF in melanoma
T6	Disease	195 223	BRAF in melanoma maintenance
T7	Phenotype	224 225	.
R1	isAssociatedWith	Arg1:T1	Arg2:T2
R2	isAssociatedWith	Arg1:T1	Arg2:T4
R3	isAssociatedWith	Arg1:T1	Arg2:T5
R4	isAssociatedWith	Arg1:T1	Arg2:T6
R5	isAssociatedWith	Arg1:T1	Arg2:T7
R6	isAssociatedWith	Arg1:T2	Arg2:T1
R7	isAssociatedWith	Arg1:T2	Arg2:T3
R8	isAssociatedWith	Arg1:T2	Arg2:T4
R9	isAssociatedWith	Arg1:T2	Arg2:T5
R10	isAssociatedWith	Arg1:T2	Arg2:T6
R11	isAssociatedWith	Arg1:T2	Arg2:T7
R12	isAssociatedWith	Arg1:T3	Arg2:T1
R13	isAssociatedWith	Arg1:T3	Arg2:T2
R14	isAssociatedWith	Arg1:T3	Arg2:T4
R15	isAssociatedWith	Arg1:T3	Arg2:T5
R16	isAssociatedWith	Arg1:T3	Arg2:T6
R17	isAssociatedWith	Arg1:T3	Arg2:T7
R18	influences	Arg1:T4	Arg2:T1
R19	influences	Arg1:T4	Arg2:T2
R20	treats	Arg1:T4	Arg2:T3
R21	influences	Arg1:T4	Arg2:T5
R22	influences	Arg1:T4	Arg2:T6
R23	influences	Arg1:T4	Arg2:T7
R24	influences	Arg1:T5	Arg2:T1
R25	influences	Arg1:T5	Arg2:T2
R26	treats	Arg1:T5	Arg2:T3
R27	influences	Arg1:T5	Arg2:T4
R28	influences	Arg1:T5	Arg2:T6
R29	influences	Arg1:T5	Arg2:T7
R30	influences	Arg1:T6	Arg2:T1
R31	influences	Arg1:T6	Arg2:T2
R32	influences	Arg1:T6	Arg2:T3
R33	influences	Arg1:T6	Arg2:T4
R34	influences	Arg1:T6	Arg2:T5
R35	influences	Arg1:T6	Arg2:T7
R36	influences	Arg1:T7	Arg2:T1
R37	influences	Arg1:T7	Arg2:T2
R38	influences	Arg1:T7	Arg2:T4
R39	influences	Arg1:T7	Arg2:T5
R40	isEquivalentTo	Arg1:T7	Arg2:T6
